Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy By Ogkologos - August 25, 2025 541 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in... December 10, 2020 EMA Recommends Granting a Marketing Authorisation for Datopotamab Deruxtecan February 20, 2025 Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group... September 13, 2024 Over 600 people in England set to benefit from innovative lung... December 1, 2021 Load more HOT NEWS Learning to Advocate for Yourself – An Important Skill! ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3...
